Trial Profile
Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Enoxaparin sodium (Primary) ; Rivaroxaban (Primary)
- Indications Haemorrhage
- Focus Therapeutic Use
- 14 May 2014 New trial record